Rethink CAR T cell therapy with a scalable RNA lipid nanoparticle platform

Tuesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET

Sponsor

Rethink CAR T cell therapy with a scalable RNA lipid nanoparticle platform

Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.

Advance T cell therapy research into the clinic with a novel lipid nanoparticle (LNP) platform. This platform enables cell therapy researchers to establish a clinically-relevant method for ex vivo gene delivery and editing Genetically modifying immune cells against tumors is a promising anti-cancer therapy. However, current gene delivery methods have significant challenges, hindering further innovations in cell therapies. Non-viral electroporation method can be harsh on cells, making it difficult to generate quality cells at high yields, whereas conventional viral vector delivery method is expensive and cumbersome to manufacture.GenVoy-ILM™ T Cell Kit for mRNA, a first-to-market lipid nanoparticle reagent kit, overcomes these limitations to enable RNA delivery into human primary T cells with high efficiency while maintaining high cell viability. This kit can be easily tuned and scaled across the NanoAssemblr® NxGen microfluidic platform from discovery to the clinic.

Challenges with current ex vivo gene delivery and editing strategies for cell therapies
Potential of RNA-LNPs in cell therapies
Introduction of GenVoy™ lipid nanoparticle delivery and NanoAssemblr® microfluidic platform
Latest proof-of-concept study results

Angela Zhang PhD

Senior Product Manager at Precision NanoSystems Inc

Dr. Angela Zhang is a Senior Product Manager at Precision NanoSystems Inc. After obtaining her PhD in Immunology at the University of Toronto, Angela had various roles in the immunotherapy and epithelial stem cell biology areas prior to joining Precision NanoSystems in 2020. She is passionate about enabling broader adoption of lipid nanoparticles by researchers and drug developers, particularly those working in cell therapies.

Reka Geczy PhD

Product Development Scientist at Precision NanoSystems Inc

Reka holds a PhD in Pharmaceutical Sciences from the University of British Columbia with high impact publications at the interface of microfluidics and drug delivery. After her postdoc at the University of Copenhagen, she joined Precision NanoSystems as a Product Development Scientist. Her team is developing potent and efficient lipid nanoparticle compositions for cell and gene therapies.